xanthine has been researched along with Coronary Disease in 21 studies
7H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-7 is protonated.
9H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-9 is protonated.
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hypoxanthine was quantified in human plasma samples obtained at various times during coronary artery bypass grafting." | 1.28 | Quantitation of hypoxanthine in plasma from patients with ischemic heart disease: adaption of a high-performance liquid chromatographic method. ( Himmel, HM; Ravens, U; Sadony, V, 1991) |
| "ISF adenosine was transiently elevated in the ischemic region, obtaining a maximum sixfold increase after 15 min of ischemia." | 1.28 | Interstitial purine metabolites during regional myocardial ischemia. ( Dorheim, TA; Mentzer, RM; Van Wylen, DG; Wang, T, 1990) |
| "Xanthine oxidase (XO) has been hypothesized to be a potential source of oxygen-derived free radicals during reperfusion of ischemic myocardium based on the fact that allopurinol, a XO-inhibitor, can reduce reperfusion injury." | 1.27 | Role of xanthine oxidase inhibitor as free radical scavenger: a novel mechanism of action of allopurinol and oxypurinol in myocardial salvage. ( Clement, R; Das, DK; Engelman, RM; Otani, H; Prasad, MR; Rao, PS, 1987) |
| "Hypoxanthine levels were fivefold more in Group 1 compared with Groups 2 and 3 (p less than 0." | 1.27 | Myocardial reperfusion injury. Role of myocardial hypoxanthine and xanthine in free radical-mediated reperfusion injury. ( Abd-Elfattah, AS; Brunsting, LA; Doherty, NE; Jessen, ME; Lekven, J; Wechsler, AS, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (61.90) | 18.7374 |
| 1990's | 6 (28.57) | 18.2507 |
| 2000's | 1 (4.76) | 29.6817 |
| 2010's | 1 (4.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Watt, J | 1 |
| Ewart, MA | 1 |
| Greig, FH | 1 |
| Oldroyd, KG | 1 |
| Wadsworth, RM | 1 |
| Kennedy, S | 1 |
| FUKUDA, H | 1 |
| FERNANDEZBLANCO, E | 1 |
| DEFERNANDEZBLANCO, JF | 1 |
| AGUSTINARZENO, J | 1 |
| KIMURA, E | 1 |
| USHIYAMA, K | 1 |
| KOJIMA, N | 1 |
| SATAKE, K | 1 |
| Harmsen, E | 3 |
| de Tombe, PP | 3 |
| de Jong, JW | 4 |
| Achterberg, PW | 1 |
| Keijzer, E | 1 |
| Stangeland, L | 1 |
| Grong, K | 1 |
| Bakken, AM | 1 |
| Farstad, M | 1 |
| Lekven, J | 2 |
| Stanek, EJ | 1 |
| Melko, GP | 1 |
| Charland, SL | 1 |
| Tarkka, MR | 1 |
| Kaukinen, S | 1 |
| Holm, P | 1 |
| Kaukinen, U | 1 |
| Sisto, T | 1 |
| Kataja, J | 1 |
| Huang, WQ | 1 |
| Himmel, HM | 1 |
| Sadony, V | 1 |
| Ravens, U | 1 |
| Kaneko, M | 1 |
| Hayashi, H | 1 |
| Kobayashi, A | 1 |
| Yamazaki, N | 1 |
| Dhalla, NS | 1 |
| Thomassen, A | 1 |
| Nielsen, TT | 1 |
| Bagger, JP | 1 |
| Pedersen, AK | 1 |
| Henningsen, P | 1 |
| Bergsland, J | 1 |
| Lobalsamo, L | 1 |
| Lajos, PS | 1 |
| Feldman, MJ | 1 |
| Vanwylen, DG | 1 |
| Dorheim, TA | 1 |
| Wang, T | 1 |
| Mentzer, RM | 1 |
| Van Wylen, DG | 1 |
| Czarnecki, W | 1 |
| Ruzyllo, W | 1 |
| Huizer, T | 1 |
| Herbaczyńska-Cedro, K | 1 |
| Das, DK | 1 |
| Engelman, RM | 1 |
| Clement, R | 1 |
| Otani, H | 1 |
| Prasad, MR | 1 |
| Rao, PS | 1 |
| Abd-Elfattah, AS | 1 |
| Jessen, ME | 1 |
| Doherty, NE | 1 |
| Brunsting, LA | 1 |
| Wechsler, AS | 1 |
| Humphrey, SM | 1 |
| Vanderwee, MA | 1 |
| Gavin, JB | 1 |
| Beresewicz, A | 1 |
| Karwatowska-Kryńska, E | 1 |
| Firek, L | 1 |
| Charlat, MI | 1 |
| O'Neill, PG | 1 |
| Egan, JM | 1 |
| Abernethy, DR | 1 |
| Michael, LH | 1 |
| Myers, ML | 1 |
| Roberts, R | 1 |
| Bolli, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase III Study of Intravenous Glutamate Infusion for Metabolic Protection of the Heart in Surgery for Unstable Coronary Artery Disease[NCT00489827] | Phase 3 | 865 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients with atrial fibrillation recorded postoperatively (NCT00489827)
Timeframe: Hospital stay
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 147 |
| Saline Infusion | 152 |
ICU duration of stay (hours) (NCT00489827)
Timeframe: ICU stay
| Intervention | hours (Median) |
|---|---|
| Intravenous Glutamate | 21 |
| Saline Infusion | 21 |
(NCT00489827)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 31 |
| Saline Infusion | 25 |
Incidence of Postoperative stroke < 24 hours of surgery verifed by CT-scan (NCT00489827)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 4 |
| Saline Infusion | 6 |
Hemodynamic instability despite inotropes or need for IABP at the end of surgery in patients with severely reduced left ventricular ejection fraction (LVEF<0.40) (NCT00489827)
Timeframe: End of surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 1 |
| Saline Infusion | 5 |
maximum p-creatinine value recorded postoperatively < 30 days (NCT00489827)
Timeframe: 30 days
| Intervention | µmol/L (Mean) |
|---|---|
| Intravenous Glutamate | 106 |
| Saline Infusion | 106 |
Severe circulatory failure according to prespecified criteria as judged by a blinded endpoints committee in CCS class IV patients (NCT00489827)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 3 |
| Saline Infusion | 16 |
p-CK-MB postoperative day 1, p-troponin-T postoperative day 3 (NCT00489827)
Timeframe: perioperative
| Intervention | µg/L (Median) | |
|---|---|---|
| CK-MB day 1 | Troponin-T day 3 | |
| Intravenous Glutamate | 14 | 0.27 |
| Saline Infusion | 14 | 0.24 |
Mixed venous oxygen saturation (SvO2) measured at weaning from cardiopulmonary bypass and on arrival to ICU (NCT00489827)
Timeframe: Until arrival to ICU
| Intervention | percentage of saturated hemoglobin (Mean) | |
|---|---|---|
| SvO2 at weaning from CPB | SvO2 on arrival to ICU | |
| Intravenous Glutamate | 72.0 | 65.0 |
| Saline Infusion | 72.2 | 64.9 |
1 review available for xanthine and Coronary Disease
| Article | Year |
|---|---|
Xanthine interference with dipyridamole-thallium-201 myocardial imaging.
Topics: Adenosine; Animals; Caffeine; Coronary Disease; Dipyridamole; Dogs; False Negative Reactions; Heart; | 1995 |
2 trials available for xanthine and Coronary Disease
| Article | Year |
|---|---|
The effect of reactive oxygen species on whole blood aggregation and the endothelial cell-platelet interaction in patients with coronary heart disease.
Topics: Aged; Blood Platelets; Cell Communication; Coronary Disease; Endothelial Cells; Endothelium, Vascula | 2012 |
Allopurinol does not increase free radical scavenging capacity during reperfusion in coronary artery bypass graft patients.
Topics: Aged; Allopurinol; Analysis of Variance; Coronary Artery Bypass; Coronary Disease; Double-Blind Meth | 2000 |
18 other studies available for xanthine and Coronary Disease
| Article | Year |
|---|---|
[STUDIES ON THE SYNTHESES OF XANTHINE DERIVATIVES. V. SYNTHESES OF SOME 7-(2-HYDROXY-3-ALKYLAMINOPROPYL)THEOPHYLINE AND 1-(2-HYDROXY-3-ALKYLAMINOPROPYL)THEOBROMINE AND THEIR DERIVATIVES].
Topics: Chemistry, Pharmaceutical; Coronary Disease; Pharmacology; Pharmacy; Pregnenes; Research; Theobromin | 1963 |
[7-(3-(METHYL-OXYETHYLAMINE)-2-OXYPROPYL)-1, 3-DIMETHYL-XANTHINE NICOTINATE IN CHRONIC OBLITERATING ANGIOPATHIES].
Topics: Arteriosclerosis; Arteriosclerosis Obliterans; Cholesterol; Coronary Disease; Humans; Intracranial A | 1963 |
Clinical evaluation of TH-24, a newly synthetized xanthine derivative, in the treatment of the coronary artery disease.
Topics: Cardiotonic Agents; Coronary Artery Disease; Coronary Disease; Humans; Xanthine; Xanthines | 1962 |
Enhanced ATP and GTP synthesis from hypoxanthine or inosine after myocardial ischemia.
Topics: Adenosine Triphosphate; Animals; Coronary Disease; Guanosine Triphosphate; Hypoxanthine; Hypoxanthin | 1984 |
The Ca-antagonist nifedipine reduces purine nucleoside and oxypurine release from ischemic heart.
Topics: Adenine Nucleotides; Animals; Coronary Circulation; Coronary Disease; Heart; Hypoxanthine; Hypoxanth | 1984 |
Diltiazem administered before or during myocardial ischemia decreases adenine nucleotide catabolism.
Topics: Adenine Nucleotides; Adenosine; Adenosine Triphosphate; Animals; Benzazepines; Coronary Circulation; | 1984 |
Effects of timolol on adenine nucleotide catabolism in cat hearts with acute regional ischaemia.
Topics: Acute Disease; Adenine Nucleotides; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Tripho | 1984 |
Quantitation of hypoxanthine in plasma from patients with ischemic heart disease: adaption of a high-performance liquid chromatographic method.
Topics: Allopurinol; Chromatography, High Pressure Liquid; Coronary Disease; Guanosine; Humans; Hypoxanthine | 1991 |
Stunned myocardium and oxygen free radicals--sarcolemmal membrane damage due to oxygen free radicals.
Topics: Adenosine Triphosphatases; Animals; Calcium; Catalase; Cell Membrane; Coronary Disease; Free Radical | 1991 |
Antiischemic and metabolic effects of glutamate during pacing in patients with stable angina pectoris secondary to either coronary artery disease or syndrome X.
Topics: Adult; Angina Pectoris; Cardiac Pacing, Artificial; Coronary Angiography; Coronary Disease; Electroc | 1991 |
Oxypurinol protects normothermic ischemic hearts.
Topics: Animals; Blood Pressure; Cardiac Output; Coronary Disease; Heart Arrest, Induced; Hypoxanthine; Hypo | 1990 |
Interstitial purine metabolites during regional myocardial ischemia.
Topics: Adenosine; Animals; Coronary Circulation; Coronary Disease; Dialysis; Dogs; Extracellular Space; Fem | 1990 |
Apparent inosine uptake by the human heart.
Topics: Adult; Cardiac Catheterization; Coronary Disease; Female; Hemodynamics; Humans; Hypoxanthine; Hypoxa | 1989 |
Role of xanthine oxidase inhibitor as free radical scavenger: a novel mechanism of action of allopurinol and oxypurinol in myocardial salvage.
Topics: Adenosine Triphosphate; Allopurinol; Animals; Coronary Disease; Female; Free Radicals; Heart; Hydrox | 1987 |
Myocardial reperfusion injury. Role of myocardial hypoxanthine and xanthine in free radical-mediated reperfusion injury.
Topics: Adenine; Adenine Nucleotides; Animals; Coronary Disease; Dogs; Female; Free Radicals; Heart; Heart V | 1988 |
Transmural differences in the postischemic recovery of cardiac energy metabolism.
Topics: Adenine Nucleotides; Animals; Coronary Disease; Energy Metabolism; Hypoxanthine; Hypoxanthines; In V | 1988 |
Effects of in vitro generated oxygen free radicals on transmembrane potentials in ventricular cardiac muscle.
Topics: Animals; Arrhythmias, Cardiac; Coronary Disease; Female; Free Radicals; Guinea Pigs; In Vitro Techni | 1987 |
Evidence for a pathogenetic role of xanthine oxidase in the "stunned" myocardium.
Topics: Allopurinol; Animals; Blood Gas Analysis; Body Temperature; Coronary Circulation; Coronary Disease; | 1987 |